. . . . . . . . . "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." . . . . . . "adults" . . "2021-08-26T09:18:29.198055"^^ . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" . "Xul0Er1OEZlq+dVjbQ0m1pCd5STdOYyyHJARC23oqe/5lhRL5V1pr6zj39fii3udiM/oFfnA67tJ2ToNRVXdbaWJ1UlSjx04RpgdSwAQUQcNm57ILUyuwyImpyCBmkQ4q1t5r9ie/+FSFHAXAtrok87vzn6Aarb0u4QuYXZyhV4=" . . "2021-08-26T09:18:29.198055"^^ . . .